Inixaciclib

**Semantic type:** Pharmacologic Substance

**Definition:** An orally bioavailable inhibitor of cyclin-dependent kinase (CDK) types 2 (CDK2), 4 (CDK4) and 6 (CDK6), with potential antineoplastic activity. Upon oral administration, inixaciclib selectively targets and inhibits CDK2, CDK4 and CDK6, which inhibits the phosphorylation of retinoblastoma protein (Rb) early in the G1 phase and prevents CDK-mediated G1-S-phase transition. This leads to cell cycle arrest, the induction of apoptosis, and the inhibition of tumor cell proliferation. CDKs are serine/threonine kinases that are important regulators of cell cycle progression and cellular proliferation and are upregulated in many tumor cell types. NUV-422 may be able to penetrate through the blood-brain barrier (BBB).

**Synonyms:** - CDK2/4/6 Inhibitor NUV-422 - Cyclin-dependent Kinase 2/4/6 Inhibitor NUV-422 - INIXACICLIB - NUV 422 - NUV-422 - NUV422